|
COPYRIGHT 2004 International Medical News Group
SAN FRANCISCO -- When added to standard therapies, omalizumab, an anti-IgE antibody, appears effective in treating patients who have both moderate to severe allergic asthma and persistent allergic rhinitis, according to a poster presented by Dr. R. Dahl at the annual meeting of the American Academy of Allergy, Asthma,...
Read the full article for free courtesy of your local library.
|